Silver Book Fact

A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • 91 medicines are currently in development for Alzheimer’s disease.  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • Impact of Slowed Progression by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050